Institut de Cancerologie Strasbourg Europe Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04378920
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Institut de Cancerologie Strasbourg Europe | Institut de cancérologie Strasbourg Europe

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Hematologic Neoplasms (Phase 2)

Neoplasms (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7